Agenus

Health, Investment, Medical, Science

BEST is envisioned as a way to democratize financing through targeted investments for specific therapeutic drug products. Tokenization will enable accredited investors the opportunity to invest directly in a single asset, Agenus’ anti-PD-1 antibody (AGEN2034), while preserving shareholder equity.

 

B.E.S.T is a revolutionary tool enabling accredited investors to invest in specific late stage products:

  • B.E.S.T will be built upon blockchain technology, B.E.S.T is NOT a cryptocurrency
  • The first B.E.S.T is offered for a late stage product, AGEN2034, a PD-1 antibody
  • All PD-1 molecules that entered late stage development have received FDA approval. AGEN2034, Agenus’ PD-1 is in late stage development for patients with advanced cervical cancer

Token sale completed on 13 March
Goal: 100,000,000 USD
Website
chrome_2019-02-21_23-49-28
Token Sale: 22 February — 13 March 2019
Fundraising Goal
Issuance Partner
Investor Requirements
Token Issue

LATEST NEWSLETTER: Learn what makes our proprietary QS-21 Stimulon a potent #adjuvant and about our efforts to #innovate QS-21 production, supported by a grant of ~1M, recently awarded to $AGEN by the Bill & Melinda Gates Foundation @gatesfoundation. Read https://t.co/coxJZSc2ju

Load More...
stofilterstofilter
This website uses cookies and asks your personal data to enhance your browsing experience.